Indication-specific dosing for Intelectol (vinpocetine), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost information.

Sections

Sections Vinpocetine
Suggested Dosing
Suggested Uses
Interactions
Adverse Effects
Warnings
Pregnancy
Pharmacology

Suggested Dosing

Cognitive impairment due to vascular disease

5-10 mg PO TID

Take with food

Suggested Uses

Increases cerebral blood flow and metabolism, anticonvulsation, cognition enhancement, neuroprotection, antioxidation, cerebral vasodilation

Efficacy

Some clinical studies show prophylactic effects in ischemic stroke & cognitive improvement

Sold as a legal pharmaceutical product in Japan, Europe, & Mexico

Not beneficial in Alzheimer's disease

Interaction Checker

Enter a drug name and Vinpocetine

No Results

No Interactions Found

Interactions Found

Contraindicated

Serious - Use Alternative

Significant - Monitor Closely

Minor

All Interactions Sort By:

Contraindicated (0)

Serious - Use Alternative (0)

Monitor Closely (0)

Minor (15)

alprazolam
alprazolam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
chlordiazepoxide
chlordiazepoxide increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
clonazepam
clonazepam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
clorazepate
clorazepate increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
diazepam
diazepam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
estazolam
estazolam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
flurazepam
flurazepam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
loprazolam
loprazolam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
lorazepam
lorazepam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
lormetazepam
lormetazepam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
midazolam
midazolam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
oxazepam
oxazepam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
quazepam
quazepam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
temazepam
temazepam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
triazolam
triazolam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).

alprazolam
Minor (1)alprazolam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
chlordiazepoxide
Minor (1)chlordiazepoxide increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
clonazepam
Minor (1)clonazepam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
clorazepate
Minor (1)clorazepate increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
diazepam
Minor (1)diazepam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
estazolam
Minor (1)estazolam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
flurazepam
Minor (1)flurazepam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
loprazolam
Minor (1)loprazolam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
lorazepam
Minor (1)lorazepam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
lormetazepam
Minor (1)lormetazepam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
midazolam
Minor (1)midazolam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
oxazepam
Minor (1)oxazepam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
quazepam
Minor (1)quazepam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
temazepam
Minor (1)temazepam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
triazolam
Minor (1)triazolam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).

Frequency Not Defined

Nausea

Dizziness

Insomnia

Drowsiness

Dry mouth

Transient hypotension

Transient tachycardia

Pressure-type headache

Facial flushing

Prolonged use: slight reductions in both systolic & diastolic blood pressure & blood glucose

Contraindications

Hypersensitivity to vinpocetine or other vinca alkaloids

Pts in incomplete homeostasis after cerebral haemorrhage

Pregnancy, lactation

<18 years old

Cautions

Hemophilia, heart problems or low blood pressure

Monitor INR in patients on warfarin

Pregnancy & Lactation

Pregnancy Category: avoid

Lactation: avoid

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Pharmacology

Peak Plasma Time: 1-1.5 hr

Half-Life, elimination: 1-2 hr

Absorption: 60% with food, 7% without

Metabolism: extensively to inactive apovincaminic acid in liver

Excretion: urine

Mechanism of Action

Shown to inhibit cGMP phosphodiesterase that has may result in increased cerebral blood flow

Reported to have calcium-channel blocker, voltage-gated sodium channel blocker, & acetylcholine release activities

Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.

[CLOSE WINDOW]